Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Update

Jaguar Health, Inc. (NASDAQ:JAGX) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 430,700 shares, an increase of 29.6% from the October 31st total of 332,300 shares. Approximately 5.6% of the company’s stock are short sold. Based on an average daily trading volume, of 266,600 shares, the short-interest ratio is presently 1.6 days.

Jaguar Health Stock Performance

Shares of JAGX traded down $0.02 during mid-day trading on Monday, hitting $1.02. The stock had a trading volume of 19,880 shares, compared to its average volume of 716,576. Jaguar Health has a fifty-two week low of $0.90 and a fifty-two week high of $24.30. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.84 and a quick ratio of 1.36. The company’s fifty day simple moving average is $1.12 and its two-hundred day simple moving average is $2.37.

Institutional Trading of Jaguar Health

An institutional investor recently bought a new position in Jaguar Health stock. Virtu Financial LLC bought a new stake in shares of Jaguar Health, Inc. (NASDAQ:JAGX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned about 0.28% of Jaguar Health at the end of the most recent quarter. Institutional investors own 12.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research report on Friday, September 13th.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.